The dangers of mail-in genetic testing
By Daniel Munro,
Maclean's
| 06. 05. 2017
The risks from home-based genetic testing kits to privacy as well as people’s health appear far greater than the supposed benefits.
If you could have an early warning about your genetic risk of acquiring a serious disease or health condition, would you want it? For a few hundred dollars and a saliva sample, private companies will analyze parts of your genome and send you a report that quantifies your predisposition for conditions like Huntington’s disease and late-onset Alzheimer’s disease, and your carrier status for inherited conditions such as cystic fibrosis, Tay-Sach’s disease and sickle cell anemia. Armed with that information you could make lifestyle changes to lower risk, seek medical advice and treatment, and talk with friends and family about your plans for managing possible symptoms and outcomes.
But before we swab our cheeks and mail saliva samples to private labs, we should try to answer a few questions. Are we equipped to make sense of the test results? Could our misunderstanding produce more harm than good—for both individuals and society? How much should we worry about how DNA samples...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...